12 results about "Bacterial host" patented technology

DEPCT6604 / 07 / 2566 This invention involves a DNA structure suitable for expression. Recombinant proteins in bacterial host cells that include the following DNA structure: Coding nucleotide sequence: promoter rhaBAD, RhaR transcription activater, RhaS Transcription activators, antibiotic resistance indicators, actively linked promoters. Along with nucleic acids that encode indicators of antibiotic resistance, the terminators rrnBT1 and rrnBT2. The point for initiating self-replication, pMB1, is a DNA structure that may also be assembled with sequences. The nucleotides that encode the recombinant protein are functionally linked to the promoter. This invention, rhaBAD, involves, in addition to a vector and a bacterial host cell that are combined. Given this DNA structure and the method of producing recombinant proteins... By contacting the host bacterial cells with rhamnose, the expression of these cells is stimulated. Of the aforementioned recombinant proteins;

The application provides a newly isolated Pseudomonas plecoglossicida phage, a preparation method and application thereof. The phage is preserved in the China Center for Type Culture Collection on February 15, 2023, and the preservation number is CCTCC NO:M 2023124. The application discloses a phage which can efficiently inhibit the growth of Pseudomonas plecoglossicida, and can only infect Pseudomonas plecoglossicida, and has high specificity. The phage can be applied to the fields of agriculture, medicine, environment and the like to resist the bacterial host, and has a good development prospect as an antibiotic substitute.

The present disclosure provides modified bacterial cell lysate compositions and methods for cell-free phage synthesis (CFBS) using the compositions to produce a wide range of phage species. Also disclosed herein are bacteriophage engineering methods for converting a lysogenic bacteriophage to a lytic bacteriophage, and methods for producing a genetically modified bacteriophage species that target a wider range of bacterial host strains than a wild type bacteriophage species.

The present disclosure relates to immunogenic polypeptides for eliciting an immune response against influenza. These polypeptides are suitable for use in combination with hemagglutinin (HA)-containing influenza vaccine formulations. Also disclosed are polynucleotides encoding the polypeptides, DNA constructs, recombinant vectors, and recombinant bacterial host cells for expression. The disclosure further provides vaccine compositions comprising the immunogenic polypeptides and pharmaceutically acceptable carriers. Methods for producing the vaccine composition and eliciting an immune response against influenza infection in a subject are also described.

The invention discloses a traceability analysis and multi-habitat homology evaluation method for antibiotic drug-resistant genes in an environmental sample, which is used for cross-habitat transmission and potential source identification of the drug-resistant genes. Comprising the following steps: 1) establishing a multivariate abundance matrix of antibiotic drug-resistant genes in environmental samples, constructing a drug-resistant gene traceability model by utilizing a machine learning algorithm, and accurately predicting potential contribution proportions of different habitats to a target habitat resistance group; and 2) aiming at the identified source habitat, reconstructing a bacterial genome through a genome assembly and binning technology, identifying homologous drug-resistant genes of the source-sink habitat by utilizing multi-sequence alignment and phylogenetic analysis, constructing a multi-medium transmission map of the drug-resistant genes and a transmission network between bacterial hosts, and clarifying connectivity and a transmission mechanism between habitats. According to the method, machine learning traceability and gene homology analysis are integrated, so that systematic evaluation of drug-resistant gene cross-habitat transmission is realized, and technical support is provided for pollution source identification and risk prevention and control of bacterial drug resistance.

The present invention relates to an isolated recombinant polypeptide comprising a fibrinogen gamma chain and a His tag. The present invention also relates to a nucleic acid encoding said polypeptide, a vector comprising said nucleic acid, a host cell, preferably a bacterial host cell, comprising said nucleic acid or vector, a biological hybrid material comprising a conjugate comprising said polypeptide, uses of the above, and a method of manufacturing said polypeptide.

The present invention provides recombinant gram-negative host cells that do not degrade protease-sensitive recombinant proteins yet grow to high cell density, methods for the use of these host cells to produce high-quality recombinant proteins, including antibodies and antibody fragments, at high yield, as well as compositions and methods relating to periplasmic expression of recombinant proteins or polypeptides of interest in host cells.

The present disclosure provides genetically modified Salmonella (GMS) strains with enhanced self-destructing and tumor-navigating activity.

The invention provides a process for manufacturing certolizumab pegol from bacterial host cells. The invention provides refolding process of certolizumab wherein the solubilized solution of heavy chain and light chain of certolizumab is treated with refolding buffer under suitable conditions including pII, temperature, and incubation period to obtain high quality and quantity of refolded protein. The invention further provides efficient pegylation process to obtain certolizumab pegol in good yields.

This invention relates to a novel method for the targeting and mapping of phage genes that are essential or important for phage replication in their bacterial host cells, to novel methods for preventing or inhibiting the formation of progeny particles of a phage from a bacterium infected with said phage, and to novel methods for promoting the formation of phage progeny particles from a bacterium.

The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.

The present invention provides recombinant gram-negative host cells that do not degrade protease-sensitive recombinant proteins yet grow to high cell density, methods for the use of these host cells to produce high-quality recombinant proteins, including antibodies and antibody fragments, at high yield, as well as compositions and methods relating to periplasmic expression of recombinant proteins or polypeptides of interest in host cells.